key: cord-0950992-ubhv7my6 authors: Marking, U.; Havervall, S.; Greilert Norin, N.; Christ, W.; Gordon, M.; Ng, H.; Blom, K.; Phillipson, M.; Mangsbo, S.; Smed-Sorensen, A.; Nilsson, P.; Hober, S.; Aberg, M.; Klingstrom, J.; Thalin, C. title: High rate of BA.1, BA.1.1 and BA.2 in triple vaccinated date: 2022-04-03 journal: nan DOI: 10.1101/2022.04.02.22273333 sha: d0997794f83e86ffd8a4ade467059968190abf4d doc_id: 950992 cord_uid: ubhv7my6 Background: Booster vaccine doses offer protection against severe COVID-19 caused by Omicron but are less effective against infection. Characteristics such as serological correlates of protection, viral abundance and clearance of Omicron infections in triple vaccinated individuals are scarce. Methods: We conducted a 4-week twice-weekly SARS-CoV-2 qPCR screening shortly after an mRNA vaccine booster in 375 healthcare workers. Anti-Spike IgG levels and neutralization titers were determined at study start. qPCR-positive participants were sampled repeatedly for two weeks and monitored for symptoms. Result: In total 82 (cumulative incidence 22%) Omicron infections were detected, divided between BA.1, BA.1.1 and BA.2. Only 10% of infected participants remained asymptomatic. Viral load peaked at day 3 and live virus could be detected for up to 9 days after first PCR-positive sample. Presence of symptoms correlated to elevated viral load (p<0.0001), but despite resolution of symptoms most participants showed Ct levels <30 at day 9. Post-booster antibody titers were similar in those with and without subsequent breakthrough infection (p>0.05), but high antibody titers were linked to reduced viral load (p<0.01) and time to viral clearance (p<0.01). No significant differences were observed for viral load and time to viral clearance between BA.1, BA.1.1 and BA.2 infected individuals. Conclusion: We report high incidence of Omicron infections despite a recent booster vaccination in triple vaccinated individuals. Vaccine-induced antibody titres seem to play a limited role in infection risk prediction. High viral load and detection of live virus for up to nine days enables spread in a triple vaccinated population. The SARS-CoV-2 B.1.1.529 (omicron) variant has caused a considerable surge in cases, including in populations with high vaccine uptake [1] . While the now widely administered booster mRNA vaccine (third doses) have been shown to be effective against severe Covid-19 [1 2] caused by omicron, protection against infection appears limited and not sufficient to prevent viral transmission [3] . Vaccine induced serological responses correlated well with the risk of infection with the ancestral virus and pre-omicron SARS-CoV-2 variants of concern [4] [5] [6] [7] , but less is known regarding correlations between serological responses and protection against omicron infection. The omicron surge has been caused by sublineages including BA.1, BA.1.1 and BA.2 [8] . Real worl data show that BA.2 carries a transmission advantage, taking over as the dominating sublineage in several countries [9] . Mutations in the antibody target spike protein distinguish the omicron sublineages from each other, but in vitro neutralization data suggest similar vaccine induced neutralizing capacity against BA.1 and BA.2 [10] . Viral characteristics and variations in viral abundance and clearance between the sublineages are, however, not fully characterized [11] [12] [13] . Here we investigated breakthrough infections in triple-vaccinated healthcare workers (HCW) with and without prior SARS-CoV-2 infection. During the study period BA.1, BA.1.1 and BA.2 circulated in Stockholm, Sweden, allowing for a comparison of breakthrough infections with the three sublineages [8] . Serological correlates of protection against infection, symptoms and viral RNA trajectories were analyzed. Remarkably, 22% of study participants became infected during the study period, with no significant impact of pre-infection antibody titers. Viral RNA trajectories were similar and suggestive of infectivity by all omicron sublineages, implying that three vaccine doses offer limited protection against BA.1, BA.1.1 and BA.2 infections and onward transmission. The COMMUNITY study comprises 2149 HCW at Danderyd Hospital, Stockholm, Sweden, enrolled between April and May, 2020. Study participants are followed every four months since inclusion [14] [15] [16] [17] . SARS-CoV-2 infection prior to vaccination was confirmed by seroconversion at any of the follow-up visits and/or by PCR. All HCW were offered . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 3, 2022 Exclusion criteria was PCR-confirmed SARS-CoV-2 infection between first vaccination and up to 6 days after post booster blood sampling (n=40). Demographics are presented in Table 1 . To analyze viral characteristics and risk of breakthrough infections, we invited 375 participants shortly after their booster vaccine dose to a twice-weekly qPCR screening with self-administered naso-oropharyngeal/saliva swabs [18] for four weeks. All participants who had completed primary vaccination and received a BNT or a MOD booster were invited. Blood samples and qPCR tests were obtained at inclusion. Positive qPCR tests after a negative inclusion test were followed up by an extended set of self-administered swabs for qPCR every other day until 15 days post first positive sample. Participants that were qPCR positive at inclusion (n=21) were included in further screening but excluded from timedependent analyses. All study participants engaged in the extended follow-up responded to a questionnaire including a pre-defined set of symptoms (fever, sore throat, cough, headache, anosmia and rhinorrea). After a 15 days completion of follow-up sampling, participants continued in the twice-weekly screening until the end of the study period. PCR, whole genome sequencing (WGS) and virus isolation was performed as previously described [19] . The study was approved by the Swedish Ethical Review Authority (dnr 2020-01653) and conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all study participants. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In a sub-set of 86 participants (66 SARS-CoV-2 naïve and 20 recovered), neutralizing capacity against WT and omicron was performed using a micro-neutralization assay as previously described [20] . Briefly, heat-inactivated serum was 3-fold serially diluted, mixed with virus, incubated for 1 hour and finally added, in duplicates, to confluent Vero E6 cells in 96-well plates. Original SARS-CoV-2 WT and omicron BA.1 (both isolated from Swedish patients) were used. After 5 days incubation, the wells were inspected for signs of CPE by optical microscopy. Serum neutralizing activity was measured by 100% CPE inhibition (IC100). Each well was scored as either neutralizing (if no signs of CPE was observed) or nonneutralizing (if any CPE was observed). The arithmetic mean neutralization titer of the reciprocals of the highest neutralizing dilutions from the two duplicates for each sample was then calculated. Risk of breakthrough infection over four weeks screening was evaluated using survival analysis by logistic regression model adjusted for age and sex. For statistical comparisons, negative qPCR-samples were given a value of 46. Mann-Whitney U test was performed for comparisons of antibody titers between groups, peak Ct levels and number of positive days between groups, using GraphPad Prism version 9.2.0 (GraphPad Software, San Diego, California, USA). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint We recently reported increased cross-neutralization potency against SARS-CoV-2 variants following primary vaccination with two doses BNT or heterologous ChAd followed by BNT compared to two doses of ChAd [21] . Using blood samples taken before ( figure 1A ) and five weeks after (figure 1B) MOD booster vaccination, we found comparable booster anti-WT spike IgG (figure 1B), anti-WT RBD IgG (figure S1A), cross-reactive IgG capable of binding omicron BA.1 spike (figure S1B) and RBD (figure S1C) and neutralizing titers against both WT (figure S1D) and omicron BA.1 (figure S1E). As previously reported [22] SARS-CoV-2 recovered vaccinees showed stronger antibody responses than SARS-CoV-2 naïve vaccinees following primary vaccination ( Figure 1C ). This difference still remained after the booster dose ( Figure 1D ), although not as strong (fold change 2.5 vs. 8.2 for anti-spike WT IgG Taken together, these findings show that while booster vaccination may level out differences due to various prior immunizations the serological responses against omicron is clearly lower than against WT SARS-CoV-2. To investigate risk for post booster breakthrough infections with omicron, 375 triplevaccinated participants were enrolled in a qPCR-screening study early 2022. Demographics and vaccine regimens are presented in Table 2 . During this period, BA.1, BA.1.1 and BA.2 circulated in Sweden. Self-administered naso-oropharyngeal/saliva tests were performed twice weekly for four weeks (median adherence 2 samples per week, IQR 1.75-2). The total time-at-risk was 1485 person-weeks, total number of screening samples 2502. A total of 82 (22% of all tested participants) omicron breakthrough infections were detected during the four-week screening period, among which 21 were detected at study . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To address whether individuals with breakthrough infections had lower antibody responses before infection, we compared antibody titers in samples obtained at inclusion in the qPCR screening in participants that subsequently tested positive to those that remained negative throughout the screening period. Post booster anti-WT spike IgG titers ( Figure 2C ) and neutralizing titers against both WT (figure 2D) and omicron BA.1 (figure 2E) were similar in those with and without subsequent breakthrough infection (p>0.05). High binding and neutralizing antibody titers were, however, associated with lower peak viral RNA levels (p=0.001) and a faster viral clearance (p<0.005) (figure 2F-G). Among the 55 participants with symptomatic infection (91%), "common cold" symptoms dominated. Presence of symptoms at time of sampling correlated to higher viral load compared to samples from asymptomatic participants (p<0.0001) ( Figure 2H ). There was a trend towards shorter duration of symptoms in participants with pre-infection anti-WT spike . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. Logistic regression revealed no significant protection against infection by SARS-CoV-2 infection prior to booster immunization (p=0.06, table S1); 23.0% of the SARS-CoV-2 naïve (n=50) and 20.4% of the SARS-CoV-2 recovered (n=32) participants became infected. Furthermore, no significant correlation between prior infection and peak viral load (p=0.59), time to viral clearance (p=0.51) or symptom duration (p=0.14) was observed ( Figure 2I and S2F). As shown above ( Figure 1E [29] . This is of particular importance in vulnerable environments such as healthcare settings. Our data are furthermore in line with a recent report demonstrating a peak in omicron viral load 2-5 days after symptom onset [13] , where virus isolation was positive in 19% of vaccinated but not boostered infected individuals nine days after first positive qPCR test. Although post booster antibody titres were similar in participants with and without subsequent breakthrough infection in our cohort, high pre-infection titres ameliorated viral load once infected. Waning antibody titres have been shown following both primary vaccination and booster doses [30] [31] [32] . The observed association between high post booster antibody titers and a lower viral load once infected may contribute to the proposed short-term . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint mRNA booster effectiveness against onward omicron viral transmission [3 9 ], but longer follow-ups are needed to address the duration of this effect. Asymptomatic and pre-symptomatic transmissions play important roles in transmission dynamics. Accurate estimations of the number of asymptomatic infections are key in mathematic modelling and assumptions of population immunity. Less than 10% of cases in our study had an entirely asymptomatic course of infection, contradicting an early report suggesting a high rate of asymptomatic omicron infection [33] . Importantly, although Ct values were generally higher among asymptomatic and pre-symptomatic participants, several asymptomatic cases displayed low Ct values, emphasizing the role of asymptomatic transmission also in populations with a high vaccine uptake. Global surveillance data suggest a higher transmissibility of BA. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint high incidence of omicron infection in a recently triple vaccinated HCW cohort. These breakthrough infections were associated with high viral load, which likely contributes to the global surge in cases. Finally, our findings emphasize that vaccine-induced antibody titres play a limited role in omicron infection risk prediction. The authors declare no competing interests. collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar SARS-CoV-2 Omicron VOC Transmission in Danish Households Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial: medRxiv Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines Evidence for antibody as a protective correlate for COVID-19 vaccines Monitoring of the SARS-CoV-2 Omicron BA.1/BA.2 variant transition in the Swedish population reveals higher viral quantity in BA.2 cases Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households Neutralization of the SARS-CoV-2 Omicron BA.1 and BA Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant Duration of infectious virus shedding by SARS-CoV-2 Omicron variant-infected vaccinees Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines Impact of SARS-CoV-2 infection on vaccineinduced immune responses over time International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine– SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons Virological assessment of hospitalized patients with COVID-2019 Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards Vägledning om smittsamhetsbedömning vid covid-19. Stockholm: Public Health Agency of Sweden BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 3, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint 26 headache (D), and anosmia (E). Number of symptomatic days among participants with (light blue) and without (dark blue) prior infection (F). Pos; positive, sympt; symptom, Ct; cyclic threshold, ns; P > 0.05, *; P ≤ 0.05, **; P ≤ 0.01.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.04.02.22273333 doi: medRxiv preprint